Lisa White

Lisa White

Auto-generated profile, based on publicly available information

Lisa White

BIO5 Institute, University of Arizona, Tucson, AZ, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
DFDimitrios Filioglou
Dimitrios Filioglou
KKKristen Kovacs
Kristen Kovacs
BLBonnie J. Lafleur
Bonnie J. Lafleur
LWLisa M. White
Lisa M. White
Emmanuel KatsanisEmmanuel Katsanis
Emmanuel Katsanis
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for pediatric patients with hematologic malignancies. Human leukocyte antigen (HLA)-matched sibling donors (MSDs) are considered the optimal source for stem cell transplantation; however, up to 70% of patients lack an MSD. This disparity is particularly pronounced among racial and ethnic minorities, who face challenges in identifying matched unrelated donors (MUDs). Haploidentical (haplo) donors are nearly universally available and have become viable alternatives with post-transplant cyclophosphamide (PT-CY) improving immune reconstitution and reducing graft-versus-host disease (GvHD). While adult studies have demonstrated comparable outcomes between haplo-HCT and MSD-HCT, pediatric data remain limited, especially in racial and ethnic minority populations. This study aimed to compare the clinical outcomes of myeloablative conditioning (MAC) haplo-HCT versus MSD-HCT in pediatric and adolescent/young adult (AYA) patients with hematologic malignancies, predominantly from Hispanic and other minority backgrounds. A retrospective single-center analysis was conducted on 72 pediatric and AYA patients (0-28 years) with hematologic malignancies who underwent MAC followed by either T-cell-replete haplo-HCT (n=43) or MSD-HCT (n=29) between October 2013 and March 2025. Conditioning regimens included total body irradiation (TBI)- or busulfan-based protocols. GvHD prophylaxis consisted of PT-CY ± bendamustine (PT-BEN) with tacrolimus-mycophenolate mofetil (haplo-HCT) or methotrexate-cyclosporine (MSD-HCT). At a median follow-up of 39.4 months (MSD-HCT) and 48.7 months (haplo-HCT), OS was 74.5% for MSD-HCT and 70.1% for haplo-HCT (P=0.89), while LFS was 70.6% and 67.8%, respectively (P=0.87). Relapse rates (26.8% vs. 23.0%; P=0.49) and NRM (13.1% vs. 9.8%; P=0.95) were comparable between groups. The cumulative incidence of grade III-IV acute GvHD was higher, though not statistically significant, in haplo-HCT (19.4% vs. 7.3%; P=0.17), whereas chronic GvHD rates were 35.9% (MSD) vs. 23.9% (haplo) (P=0.25). GvHD-free, relapse-free survival (GRFS) was 60.1% for MSD-HCT versus 54.1% for haplo-HCT (P=0.83). Haplo-HCT recipients had higher rates of cytomegalovirus (CMV) reactivation requiring therapy (40% vs. 7%; P=0.002). Donor age was independently associated with increased chronic GvHD risk in multivariable analyses. In this predominantly Hispanic pediatric and AYA cohort, haplo-HCT with PT-CY achieved survival, relapse, and NRM outcomes comparable to MSD-HCT, supporting its role as a practical alternative when MSDs are unavailable. Although haplo-HCT was associated with a higher risk of CMV reactivation and a non-significant trend toward increased severe acute GvHD, overall GvHD rates were manageable. Donor age emerged as a key predictor of chronic GvHD, underscoring its importance in haploidentical donor selection. These findings highlight haplo-HCT as an effective and accessible transplant option for minority populations with limited donor availability.

26 January 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
BLBonnie J LaFleur
Bonnie J LaFleur
CCClara Curiel-Lewandrowski
Clara Curiel-Lewandrowski
ETEdgar Tapia
Edgar Tapia
JPJoel Parker
Joel Parker
LWLisa White
Lisa White
ASAndrew P. South
Andrew P. South

1 December 2023 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
BLBonnie J LaFleur
Bonnie J LaFleur
LWLisa White
Lisa White
MDMichael D. Dake
Michael D. Dake
JNJanko Z. Nikolich
Janko Z. Nikolich
RSRyan Sprissler
Ryan Sprissler
DBDeepta Bhattacharya
Deepta Bhattacharya
Uptake of mRNA vaccines, especially booster immunizations, against COVID-19 has been lower than hoped, perhaps in part due to their reactogenicity. Analgesics might alleviate symptoms associated with vaccination, but they might also impact immune responses. We semiquantitatively measured Ab responses following COVID-19 vaccination in 2354 human participants surveyed about analgesic use after vaccination. Participants who used nonsteroidal anti-inflammatory drugs or acetaminophen after vaccination showed elevated Ab levels against the receptor-binding domain of Spike protein relative to those who did not use analgesics. This pattern was observed for both mRNA-1273 and BNT162b2 and across age groups. Participants who used analgesics more frequently reported fatigue, muscle aches, and headaches than did those who did not use painkillers. Among participants who reported these symptoms, we observed no statistically significant differences in Ab levels irrespective of analgesic use. These data suggest that elevated Ab levels are associated with symptoms and inflammatory processes rather than painkiller use per se. Taken together, we find no evidence that analgesic use reduces Ab responses after COVID-19 vaccination. Recommendation of their use to alleviate symptoms might improve uptake of booster immunizations.